Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BAY3630942
- Development stage
- Phase 1
- Lead developer
- Bayer
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BAY3630942 is a monoclonal antibody developed as an imaging agent for use in patients with hepatocellular carcinoma (HCC) and other select solid tumors. It is labeled with the radioactive isotope zirconium-89 (^89Zr), allowing its distribution and localization to be tracked in the body using PET/CT imaging. The antibody targets glypican-3 (GPC3), a protein frequently expressed on the surface of liver cancer cells, enabling specific tumor targeting. The primary aim of current clinical studies is to evaluate the biodistribution, dosimetry, safety, and pharmacokinetics of BAY3630942 following pre-infusion with another monoclonal antibody-chelator conjugate (BAY3547922). This agent is not yet approved for therapeutic use but may inform future development of targeted radiotherapeutics for cancer[1][5][4].
- Other names
- BAY-3630942BAY3630942BAY 3630942
02
Targets
GPC3 (Glypican-3)
Beyond the preview
Go deeper on BAY3630942.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BAY3630942.